P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis

Trifluridine/tipiracil (TAS102) has been shown to improve survival in later lines of treatment metastatic colorectal cancer patients, irrespective RAS status. This study aimed retrospectively assess the efficacy TAS102 relation extended evaluation a multi-center real-world setting. Nine Institution from Central-Southern Italy were involved study. Main inclusion criteria were: availability evaluation, data concerning time progression (TTP) and overall (OS). Primary endpoint was OS, independently line (>2), different mutations. Data 866 regorafenib and/or TAS102-treated patients collected. available for 584. In present 361 have enrolled. Patients divided six groups: WT (RAS wild-type), 154 pts; Codon 12 (KRAS codon mutation), 81 13 37 Rare 61 146 mutation or NRAS mutations), 33 G12C G12c G12D 44 pts. Baseline characteristics well-balanced between groups. No significant differences OS groups observed (p 0.09), with trend better favor (median 9 m when compared 7 population). terms TTP 0.8). Accordingly, toward 4.0) comparison 3.0 m) confirmed. Considering those who received addition (either before after, 164 patients), an advantage 0.0002) suggesting favorable prognostic factors enriched population. According treated both TAS displayed no 0.4). When considering each group separately, 102 longer receiving even (13 vs m, p 0.002), but also (10 5 0.002) (9 4 0.02) Our demonstrate that mutations do not affect outcome although observed. (before after) show TAS-related survival, probably because less aggressive disease; benefit combination is higher mutated ones subgroups (Codon rare mutations). These data, bearing mind than 50% will receive drugs, might advise anticipation (compared 102) patients.